|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Marine propellers performance and flow-field prediction by a free-wake panel method显示文摘A Boundary Element Method(BEM) hydrodynamics combined with a flow-alignment technique to evaluate blades shed vorticity is presented and applied to a marine propeller in open water. Potentialities and drawbacks of this approach in capturing propeller performance, slipstream velocities, blade pressure distribution and pressure disturbance in the flow-field are highlighted by comparisons with available experiments and RANSE results. In particular, correlations between the shape of the convected vortexsheet and the accuracy of BEM results are discussed throughout the paper. To this aim, the analysis of propeller thrust and torque is the starting point towards a detailed discussion on the capability of a 3-D free-wake BEM hydrodynamic approach to describe the local features of the flow-field behind the propeller disk, in view of applications to propulsive configurations where the shed wake plays a dominant role. | GRECO Luca MUSCARI Roberto TESTA Claudio DI MASCIO Andrea | 2014 | Journal of Hydrodynamics2014，26，5： | 4 |
| 2 | Are metabolic factors still important in the era of direct antiviral agents in patients with chronic hepatitis C?显示文摘The high rate of sustained viral response(SVR)to boceprevir or telaprevir-based triple therapy in hepatitis C(HCV)-related,non-cirrhotic na ve patients or relapsers to previous antiviral treatment leads clinicians to believe that the impact of metabolic host factors on SVR is minimal when triple therapy is used,unlike what is observed with the peginterferon and ribavirin schedules.This concept is strongly expressed by some opinion leaders on the basis of the data derived from subanalyses of registrative trials as well as from a post-hoc analysis of the phaseⅡC208 clinical trial.The perception of unrestrainable therapeutic success with the use of newer,more powerful antivirals is now reinforced by the brilliant results obtained with sofosbuvir,an HCV NS5B polymerase inhibitor,as well as by the data from the phaseⅡandⅢstudies on the various combinations of second-generation NS3/4A inhibitors and NS5A and/or NS5B inhibitors.However,a great deal of concern has emerged from the real world scenario in which patients are often older and have more comorbidities than patients in the'world of trials'.Furthermore,many of them have advanced fibrosis and previous failure with peginterferon and ribavirin treatment.Some data from the recent literature suggest that the host metabolic factors may play a minor but non-negligible role in these difficult-to-treat patients,an issue that will hopefully be investigated in further studies.This editorial aims to provide a detailed analysis of the role that host metabolic factors played in the past and what role they may play in the era of direct antiviral agents. | Alessandro Grasso Federica Malfatti Roberto Testa | 2013 | World Journal of Gastroenterology2013，19，41： | 4 |
| 3 | 13 C-galactose breath test and 13 C-aminopyrine breath test for the study of liver function in chronic liver disease显示文摘 | Edoardo G. Giannini Alberto Fasoli Paolo Borro Federica Botta Federica Malfatti Alessandra Fumagalli Emanuela Testa Simone Polegato Tiziana Cotellessa Sara Milazzo Domenico Risso Roberto Testa | 2005 | Clinical Gastroenterology and Hepatology2005，，： | 1 |
| 4 | Relationship between thrombopoietin serum levels and liver function in patients with chronic liver disease related to hepatitis C virus infection显示文摘 | Edoardo Giannini Federica Botta Paolo Borro Federica Malfatti Alessandra Fumagalli Emanuela Testa Elena Podestà Bruno Chiarbonello Simone Polegato Mario Mamone Roberto Testa | 2003 | The American Journal of Gastroenterology2003，，11： | 1 |
| 5 | Liver enzyme alteration: a guide for clinicians 显示文摘 | EDOARDO G GIANNINI ROBERTO TESTA | 2005 | CMAJ2005，172，3： | 1 |
| 6 | Serum thrombopoietin levels are linked to liver function in untreated patients with hepatitis C virus-related chronic hepatitis显示文摘 | Edoardo Giannini Paolo Borro Federica Botta Alessandra Fumagalli Federica Malfatti Elena Podestà Paola Romagnoli Emanuela Testa Bruno Chiarbonello Simone Polegato Mario Mamone Roberto Testa | 2002 | Journal of Hepatology2002，，5： | 1 |
| 7 | Beneficial Effects of Intracoronary Adenosine as an Adjunct to Primary Angioplasty in Acute Myocardial Infarction显示文摘 | Mario Marzilli Enrico Orsini Paolo Marraccini Roberto Testa | 2000 | Circulation: Journal of the American Heart Association2000，，： | 1 |
| 8 | On the processing of harmonics and interharmonics:using Hanning Window in standard framework显示文摘 | Testa Alfredo Gallo Daniele Langella Roberto | 2004 | IEEE Trans on Power Delivery2004，19，1： | 1 |
| 9 | Influence of Helicobacter pylori eradication therapy on 13 C aminopyrine breath test: comparison among omeprazole-, lansoprazole-, or pantoprazole-containing regimens显示文摘 | Edoardo Giannini Paola Romagnoli Alberto Fasoli Bruno Chiarbonello Federica Malfatti Federica Botta Domenico Risso Pasquale B Lantieri Vincenzo Savarino Roberto Testa | 2000 | The American Journal of Gastroenterology2000，，10： | 1 |
| 10 | Serum leptin levels in patients with viral chronic hepatitis or liver cirrhosis显示文摘 | Roberto Testa Roberto Franceschini Edoardo Giannini Angelo Cataldi Federica Botta Alberto Fasoli Pasquale Tenerelli Ermanno Rolandi Tommaso Barreca | 2000 | Journal of Hepatology2000，，1： | 1 |
| 11 | Diagnostic potential of circulating miR-499-5p in elderly patients with acute non ST-elevation myocardial infarction显示文摘 | Fabiola Olivieri Roberto Antonicelli Maria Lorenzi Yuri D’Alessandra Raffaella Lazzarini Gabriele Santini Liana Spazzafumo Rosamaria Lisa Lucia La Sala Roberta Galeazzi Rina Recchioni Roberto Testa Giulio Pompilio Maurizio C. Capogrossi Antonio Domenico P | 2012 | International Journal of Cardiology2012，，： | 1 |
| 12 | SARS-CoV-2 in inflammatory bowel disease population:Antibodies,disease and correlation with therapy显示文摘BACKGROUND Guidelines recommend to cease inflammatory bowel disease(IBD)biologic therapy during coronavirus disease 2019(COVID-19).AIM To investigate severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)antibody positivity in an IBD cohort,COVID-19 disease severity and to evaluate the correlation with clinical/therapeutic variables.METHODS Prospective observational cohort study.IBD patients were tested for SARS-CoV-2 IgG.Data on COVID-19 disease,demographics/therapeutics and clinical features of the IBD population were collected.IgG≥7 was set for SARS-CoV-2 antibody positivity.Throat swab was performed in cases of IgG positivity.Correlations between antibody positivity or COVID-19 symptoms and therapeutic/clinical data were assessed.RESULTS In total,103 IBD patients were enrolled.Among them,18.4%had IgG≥7.Multivariate analysis of antibody positivity correlated only with IBD treatment.For IgG≥7,the odds ratio was 1.44 and 0.16 for azathioprine and mesalazine,respectively,vs biologic drugs(P=0.0157 between them).COVID-19 related symptoms were reported in 63%of patients with IgG positivity.All but one patient with COVID-19 symptoms did not require ceasing IBD treatment or hospitalization. IBDtreatment and body mass index correlated with COVID-19 disease development with symptoms.CONCLUSIONThe IBD population does not have a higher risk of severe COVID-19. The relative risk of havingSARS-CoV-2 antibodies and symptoms was higher for patients taking azathioprine, then biologictherapy and lastly mesalazine. None of the patients under biologic therapy developed severeCOVID-19. | Clara Benedetta Conti Elsa Mainardi Sara Soro Sophie Testa Annalisa De Silvestri Andrea Drago Fabrizio Cereatti Roberto Grassia | 2022 | World Journal of Gastrointestinal Endoscopy2022，14，3： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员